Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE
BackgroundReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.MethodsS...
Saved in:
| Published in | Lupus science & medicine Vol. 9; no. 1; p. e000704 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Lupus Foundation of America
01.07.2022
BMJ Publishing Group LTD BMJ Publishing Group |
| Series | Original research |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | BackgroundReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.MethodsSix women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.ResultsOf six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.ConclusionThis phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.Trial registration numberNCT03171194. |
|---|---|
| AbstractList | BackgroundReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.MethodsSix women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.ResultsOf six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.ConclusionThis phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.Trial registration numberNCT03171194. Background Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.Methods Six women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.Results Of six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.Conclusion This phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.Trial registration number NCT03171194. Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy. Six women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×10 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks. Of six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores. This phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease. NCT03171194. Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.BACKGROUNDReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.Six women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.METHODSSix women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.Of six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.RESULTSOf six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.This phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.CONCLUSIONThis phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.NCT03171194.TRIAL REGISTRATION NUMBERNCT03171194. |
| Author | Paulos, Crystal Wei, Chungwen Nietert, Paul J Wyatt, Megan Wang, Hongjun Kamen, Diane L Wallace, Caroline Gilkeson, Gary Wolf, Bethany J Li, Zihai |
| AuthorAffiliation | 1 Department of Medicine, Division of Rheumatology , Medical University of South Carolina , Charleston , South Carolina , USA 5 Department of Surgery , Medical University of South Carolina , Charleston , South Carolina , USA 2 Department of Medicine, Division of Hematology/Oncology , Ohio State Wexner Medical Center , Columbus , Ohio , USA 3 Department of Surgery , Emory University School of Medicine , Atlanta , Georgia , USA 6 Department of Public Health Sciences , Medical University of South Carolina , Charleston , South Carolina , USA 4 University of Rochester Medical Center , Rochester , New York , USA |
| AuthorAffiliation_xml | – name: 6 Department of Public Health Sciences , Medical University of South Carolina , Charleston , South Carolina , USA – name: 3 Department of Surgery , Emory University School of Medicine , Atlanta , Georgia , USA – name: 4 University of Rochester Medical Center , Rochester , New York , USA – name: 2 Department of Medicine, Division of Hematology/Oncology , Ohio State Wexner Medical Center , Columbus , Ohio , USA – name: 5 Department of Surgery , Medical University of South Carolina , Charleston , South Carolina , USA – name: 1 Department of Medicine, Division of Rheumatology , Medical University of South Carolina , Charleston , South Carolina , USA |
| Author_xml | – sequence: 1 givenname: Diane L surname: Kamen fullname: Kamen, Diane L organization: Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 2 givenname: Caroline surname: Wallace fullname: Wallace, Caroline organization: Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 3 givenname: Zihai surname: Li fullname: Li, Zihai organization: Department of Medicine, Division of Hematology/Oncology, Ohio State Wexner Medical Center, Columbus, Ohio, USA – sequence: 4 givenname: Megan surname: Wyatt fullname: Wyatt, Megan organization: Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA – sequence: 5 givenname: Crystal surname: Paulos fullname: Paulos, Crystal organization: Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA – sequence: 6 givenname: Chungwen surname: Wei fullname: Wei, Chungwen organization: University of Rochester Medical Center, Rochester, New York, USA – sequence: 7 givenname: Hongjun surname: Wang fullname: Wang, Hongjun organization: Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 8 givenname: Bethany J surname: Wolf fullname: Wolf, Bethany J organization: Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 9 givenname: Paul J surname: Nietert fullname: Nietert, Paul J organization: Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 10 givenname: Gary orcidid: 0000-0003-4228-3574 surname: Gilkeson fullname: Gilkeson, Gary email: gilkeson@musc.edu organization: Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35820718$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAUjFARLaU_gAuKxIUDATtOYu8FCVUFVlqJQ-FsPX_tepXYwXaK9r_wY3E2LbSV4OTn92bGY3ueFyfOO10ULzF6hzHp3vfTOMWqRnVdIYQoap4UZzVqScXoCp3cq0-Lixj3GYNrTChDz4pT0rIaUczOil_XYHQ6vC3tMEzO935rJfSlNkbLFEtwqpS9dcdm0HH0LurSuhLKcQe5XJcp2DzzppwGYfsjUPqgykFH7eTuMORGTMHPq9R9H2f6CMlqlw_4adMuS2hIQ97nI0wAmXw4lNebqxfFUwN91Be363nx_dPVt8sv1ebr5_Xlx00lWoJTRQTTIIQkhIABLLQSuGmVMRi3CtMOWqEEM0bRBiklJKCmE0Z2TYcVkrQj58V60VUe9nwMdoBw4B4sPzZ82HIIycpec6mANAK1StddQ0EJA7XomJZMCEaAZa0Pi9Y4iUErmW8VoH8g-nDi7I5v_Q1f1TT7q7PAm1uB4H9MOiY-2Dg_HDjtp8jrjq1QuyJ0hr5-BN37Kbj8VDOKdazJl8uoV_cd_bFyF4IMoAtABh9j_gIubcof5GeDtucY8Tlx_Jg4PieOL4nLTPyIeSf-P061cMSw_-v33_jfyKvtwg |
| CitedBy_id | crossref_primary_10_1080_14712598_2023_2205017 crossref_primary_10_4252_wjsc_v16_i2_70 crossref_primary_10_3390_ijms231710023 crossref_primary_10_1016_j_bulcan_2024_06_008 crossref_primary_10_1038_s41598_024_75776_5 crossref_primary_10_2147_JIR_S488201 crossref_primary_10_3390_cells12030348 crossref_primary_10_4049_jimmunol_2300752 crossref_primary_10_1016_j_clim_2024_110200 crossref_primary_10_1016_j_ejphar_2024_176862 crossref_primary_10_1016_S2665_9913_24_00298_4 crossref_primary_10_1016_j_jtauto_2024_100241 crossref_primary_10_1002_advs_202404064 crossref_primary_10_32604_biocell_2023_027090 crossref_primary_10_1016_j_jare_2025_01_044 crossref_primary_10_1007_s00125_023_05934_3 crossref_primary_10_4110_in_2023_23_e44 crossref_primary_10_1186_s13075_024_03435_1 crossref_primary_10_3390_ijms241210161 crossref_primary_10_1016_S2665_9913_24_00351_5 crossref_primary_10_3389_fimmu_2024_1520570 crossref_primary_10_1016_j_biochi_2024_04_009 crossref_primary_10_1016_j_yexcr_2024_114263 |
| Cites_doi | 10.1016/S0923-2508(01)01253-0 10.1038/cmi.2015.89 10.1073/pnas.0937635100 10.1177/0963689719837897 10.1177/0961203310361482 10.1016/j.cgh.2013.06.021 10.1136/annrheumdis-2017-211073 10.3390/cells8121577 10.1002/art.40142 10.1177/0961203309348983 10.1155/2013/732742 10.1038/nrdp.2016.39 10.1182/blood-2003-11-3909 10.1155/2018/3057624 10.1186/ar4677 10.1002/art.1780400928 10.1146/annurev-pathol-011110-130230 10.1016/j.stemcr.2018.01.029 10.1002/stem.1821 10.1002/art.38674 10.1155/2019/7061408 10.1016/j.jcyt.2012.10.002 10.1136/ard.2009.123463 10.1177/0961203318804922 10.1002/art.22511 10.2337/db08-0180 10.1073/pnas.0901944106 10.1016/j.imlet.2010.09.006 10.1002/stem.68 10.1172/jci.insight.99863 10.1186/s13287-018-0898-x 10.3727/096368911X582769c 10.1038/s41467-019-10491-8 10.1002/stem.2779 10.1073/pnas.240309797 10.1080/14653240600855905 10.1089/scd.2013.0023 10.1155/2014/169082 10.1097/01.TP.0000045055.63901.A9 10.1002/art.27548 10.4049/jimmunol.1401636 10.1007/s10067-014-2754-4 10.1182/blood-2002-06-1830 10.1186/s12882-018-0973-7 10.1016/j.stem.2009.02.001 10.1186/s13287-016-0303-6 10.1159/000047856 10.1053/j.gastro.2015.06.014 10.1182/blood.V99.10.3838 10.1038/nbt.2816 10.1002/art.39601 10.1016/j.immuni.2019.12.005 10.1038/sj.leu.2404996 10.1056/NEJMoa043731 10.1016/S0140-6736(08)60690-X 10.1155/2020/6518508 10.1155/2019/9757201 10.1155/2020/4327965 10.1155/2018/6241681 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU DWQXO FYUFA GHDGH K9. PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1136/lupus-2022-000704 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central BMJ Journals ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2053-8790 |
| ExternalDocumentID | oai_doaj_org_article_cda34b05de2647adbfa2b68ec8bb83a8 PMC9277402 35820718 10_1136_lupus_2022_000704 lupusscimed |
| Genre | Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: NIGMS grantid: NIH UL1 RR029882 – fundername: Lupus Foundation of America funderid: http://dx.doi.org/10.13039/100002193 – fundername: NIDDK NIH HHS grantid: R01 DK120394 – fundername: NIDDK NIH HHS grantid: R01 DK118529 – fundername: NIDDK NIH HHS grantid: R01 DK126454 – fundername: NCRR NIH HHS grantid: UL1 RR029882 – fundername: ; – fundername: ; grantid: NIH UL1 RR029882 |
| GroupedDBID | 53G 5VS 7X7 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BTFSW BTHHO CCPQU DIK FRJ FYUFA GROUPED_DOAJ H13 HMCUK HYE KQ8 M48 M~E OK1 PGMZT PHGZT PIMPY PQQKQ PROAC RHI RMJ RPM UKHRP AAYXX ADRAZ CITATION PHGZM CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-b531t-3b8eabbc333afa1bedb145dff115d176a5bdb8ffd740ddbca046bfc6461d0c763 |
| IEDL.DBID | M48 |
| ISSN | 2053-8790 |
| IngestDate | Wed Aug 27 01:31:37 EDT 2025 Thu Aug 21 13:59:34 EDT 2025 Mon Jul 21 10:19:29 EDT 2025 Fri Jul 25 02:29:23 EDT 2025 Mon Jul 21 05:43:54 EDT 2025 Thu Apr 24 22:51:04 EDT 2025 Tue Jul 01 03:07:57 EDT 2025 Thu Apr 24 22:50:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Autoimmunity B-Lymphocytes Lupus Erythematosus, Systemic |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b531t-3b8eabbc333afa1bedb145dff115d176a5bdb8ffd740ddbca046bfc6461d0c763 |
| Notes | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-4228-3574 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/lupus-2022-000704 |
| PMID | 35820718 |
| PQID | 2688684763 |
| PQPubID | 2041883 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cda34b05de2647adbfa2b68ec8bb83a8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9277402 proquest_miscellaneous_2689059372 proquest_journals_2688684763 pubmed_primary_35820718 crossref_citationtrail_10_1136_lupus_2022_000704 crossref_primary_10_1136_lupus_2022_000704 bmj_journals_10_1136_lupus_2022_000704 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-01 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Original research |
| PublicationTitle | Lupus science & medicine |
| PublicationTitleAbbrev | Lupus Sci Med |
| PublicationTitleAlternate | Lupus Sci Med |
| PublicationYear | 2022 |
| Publisher | Lupus Foundation of America BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: Lupus Foundation of America – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Galipeau (R44) 2013; 15 Di Nicola, Carlo-Stella, Magni (R11) 2002; 99 Wallace, Wu, Salem (R39) 2018; 3 Wang, Feng, Lu (R53) 2014; 66 Dominici, Le Blanc, Mueller (R6) 2006; 8 Grada, Falanga (R9) 2016; 29 Augello, Tasso, Negrini (R17) 2007; 56 Collins, Gu, Qi (R29) 2014; 193 Devine, Cobbs, Jennings (R50) 2003; 101 Abdi, Fiorina, Adra (R27) 2008; 57 Ginzler, Dooley, Aranow (R2) 2005; 353 Sedhain, Hada, Agrawal (R3) 2018; 19 Jenks, Cashman, Zumaquero (R35) 2020; 52 de Witte, Luk, Sierra Parraga (R57) 2018; 36 Miura, Gronthos, Zhao (R5) 2003; 100 Gao, Dennis, Muzic (R48) 2001; 169 Kean, Lin, Caplan (R52) 2013; 2013 Woodworth, Furst (R41) 2014; 16 Wen, Labopin, Badoglio (R43) 2019; 2019 Molendijk, Bonsing, Roelofs (R19) 2015; 149 Zhou, Li, Liao (R42) 2020; 2020 Le Blanc, Frassoni, Ball (R51) 2008; 371 Jenks, Chevalier, Ecobichon (R59) 2001; 152 Sun, Akiyama, Zhang (R22) 2009; 27 Ankrum, Ong, Karp (R26) 2014; 32 Carrillo-Galvez, Cobo, Cuevas-Ocaña (R38) 2015; 33 Jolly, Kosinski, Garris (R33) 2016; 68 Wang, Yuan, Xie (R28) 2018; 2018 Tran, Andersson, Wang (R37) 2009; 106 Geng, Li, Feng (R46) 2014; 2014 Singer, Caplan (R55) 2011; 6 Christopeit, Schendel, Föll (R13) 2008; 22 Gronthos, Mankani, Brahim (R7) 2000; 97 Tse, Pendleton, Beyer (R10) 2003; 75 Deng, Zhang, Guo (R24) 2017; 76 Carrión, Nova, Luz (R58) 2011; 135 Musiał-Wysocka, Kot, Majka (R25) 2019; 28 Karp, Leng Teo (R49) 2009; 4 Lee, Ayoub, Agrawal (R8) 2016; 7 Sun, Wang, Liang (R21) 2010; 62 Zhu, Feng (R47) 2018; 9 Gao, Bird, Meednu (R30) 2017; 69 Hochberg (R32) 1997; 40 Maidhof, Hilas (R4) 2012; 37 Bonig, Kuçi, Kuçi (R18) 2019; 8 Barbado, Tabera, Sánchez (R40) 2018; 27 Wang, Wang, Cong (R14) 2013; 22 Liang, Zhang, Hua (R16) 2010; 69 Forbes, Sturm, Leong (R12) 2014; 12 Gu, Wang, Zhang (R23) 2014; 33 Nie, Lau, Lie (R45) 2010; 19 Kaul, Gordon, Crow (R1) 2016; 2 Yuan, Qin, Wang (R56) 2019; 10 Carrion, Nova, Ruiz (R31) 2010; 19 Wang, Zhang, Liang (R20) 2018; 10 Wang, Huang, Yuan (R36) 2017; 14 Meisel, Zibert, Laryea (R54) 2004; 103 Wang, Zhang, Liang (R15) 2013; 22 Jolly (2024052110142839000_9.1.e000704.33) 2016; 68 Gao (2024052110142839000_9.1.e000704.30) 2017; 69 2024052110142839000_9.1.e000704.34 Geng (2024052110142839000_9.1.e000704.46) 2014; 2014 2024052110142839000_9.1.e000704.37 2024052110142839000_9.1.e000704.38 Barbado (2024052110142839000_9.1.e000704.40) 2018; 27 2024052110142839000_9.1.e000704.39 Le Blanc (2024052110142839000_9.1.e000704.51) 2008; 371 de Witte (2024052110142839000_9.1.e000704.57) 2018; 36 Woodworth (2024052110142839000_9.1.e000704.41) 2014; 16 Lee (2024052110142839000_9.1.e000704.8) 2016; 7 2024052110142839000_9.1.e000704.31 2024052110142839000_9.1.e000704.21 Wang (2024052110142839000_9.1.e000704.36) 2017; 14 2024052110142839000_9.1.e000704.22 2024052110142839000_9.1.e000704.24 2024052110142839000_9.1.e000704.25 Hochberg (2024052110142839000_9.1.e000704.32) 1997; 40 2024052110142839000_9.1.e000704.26 Sedhain (2024052110142839000_9.1.e000704.3) 2018; 19 2024052110142839000_9.1.e000704.27 2024052110142839000_9.1.e000704.28 2024052110142839000_9.1.e000704.5 2024052110142839000_9.1.e000704.29 Zhu (2024052110142839000_9.1.e000704.47) 2018; 9 2024052110142839000_9.1.e000704.6 2024052110142839000_9.1.e000704.7 2024052110142839000_9.1.e000704.1 2024052110142839000_9.1.e000704.2 Jenks (2024052110142839000_9.1.e000704.35) 2020; 52 Bonig (2024052110142839000_9.1.e000704.18) 2019; 8 Wang (2024052110142839000_9.1.e000704.20) 2018; 10 Wang (2024052110142839000_9.1.e000704.53) 2014; 66 Wang (2024052110142839000_9.1.e000704.15) 2013; 22 2024052110142839000_9.1.e000704.10 2024052110142839000_9.1.e000704.54 2024052110142839000_9.1.e000704.11 2024052110142839000_9.1.e000704.55 2024052110142839000_9.1.e000704.13 2024052110142839000_9.1.e000704.14 2024052110142839000_9.1.e000704.58 2024052110142839000_9.1.e000704.59 2024052110142839000_9.1.e000704.16 Yuan (2024052110142839000_9.1.e000704.56) 2019; 10 2024052110142839000_9.1.e000704.17 Forbes (2024052110142839000_9.1.e000704.12) 2014; 12 2024052110142839000_9.1.e000704.19 Maidhof (2024052110142839000_9.1.e000704.4) 2012; 37 Gu (2024052110142839000_9.1.e000704.23) 2014; 33 2024052110142839000_9.1.e000704.50 Kean (2024052110142839000_9.1.e000704.52) 2013; 2013 2024052110142839000_9.1.e000704.43 2024052110142839000_9.1.e000704.44 2024052110142839000_9.1.e000704.45 2024052110142839000_9.1.e000704.48 2024052110142839000_9.1.e000704.49 Grada (2024052110142839000_9.1.e000704.9) 2016; 29 2024052110142839000_9.1.e000704.42 |
| References_xml | – volume: 152 start-page: 725 year: 2001 ident: R59 article-title: Identification of nonessential Helicobacter pylori genes using random mutagenesis and loop amplification publication-title: Res Microbiol doi: 10.1016/S0923-2508(01)01253-0 – volume: 14 start-page: 423-431 year: 2017 ident: R36 article-title: The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus publication-title: Cell Mol Immunol doi: 10.1038/cmi.2015.89 – volume: 100 start-page: 5807 year: 2003 ident: R5 article-title: Shed: stem cells from human exfoliated deciduous teeth publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0937635100 – volume: 28 start-page: 801 year: 2019 ident: R25 article-title: The pros and cons of mesenchymal stem cell-based therapies publication-title: Cell Transplant doi: 10.1177/0963689719837897 – volume: 19 start-page: 850 year: 2010 ident: R45 article-title: Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus publication-title: Lupus doi: 10.1177/0961203310361482 – volume: 12 start-page: 64 year: 2014 ident: R12 article-title: A Phase 2 study of allogeneic mesenchymal stromal cells for Luminal crohn’s disease refractory to biologic therapy publication-title: Clinical Gastroenterology and Hepatology doi: 10.1016/j.cgh.2013.06.021 – volume: 76 start-page: 1436 year: 2017 ident: R24 article-title: A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211073 – volume: 8 start-page: 1577 year: 2019 ident: R18 article-title: Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”—outcome report of 92 patients publication-title: Cells doi: 10.3390/cells8121577 – volume: 69 start-page: 1623 year: 2017 ident: R30 article-title: Bone marrow-derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein-Interferon-β feedback loop publication-title: Arthritis & Rheumatology doi: 10.1002/art.40142 – volume: 19 start-page: 317 year: 2010 ident: R31 article-title: Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients publication-title: Lupus doi: 10.1177/0961203309348983 – volume: 2013 start-page: 1 year: 2013 ident: R52 article-title: Mscs: delivery routes and engraftment, cell-targeting strategies, and immune modulation publication-title: Stem Cells Int doi: 10.1155/2013/732742 – volume: 2 start-page: 16039 year: 2016 ident: R1 article-title: Systemic lupus erythematosus publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.39 – volume: 103 start-page: 4619 year: 2004 ident: R54 article-title: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation publication-title: Blood doi: 10.1182/blood-2003-11-3909 – volume: 2018 start-page: 1 year: 2018 ident: R28 article-title: Mesenchymal stem cell-based immunomodulation: properties and clinical application publication-title: Stem Cells Int doi: 10.1155/2018/3057624 – volume: 16 start-page: 113 year: 2014 ident: R41 article-title: Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy publication-title: Arthritis Res Ther doi: 10.1186/ar4677 – volume: 40 year: 1997 ident: R32 article-title: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis & Rheumatism doi: 10.1002/art.1780400928 – volume: 6 start-page: 457 year: 2011 ident: R55 article-title: Mesenchymal stem cells: mechanisms of inflammation publication-title: Annu Rev Pathol doi: 10.1146/annurev-pathol-011110-130230 – volume: 10 start-page: 933 year: 2018 ident: R20 article-title: A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus publication-title: Stem Cell Reports doi: 10.1016/j.stemcr.2018.01.029 – volume: 33 start-page: 183 year: 2015 ident: R38 article-title: Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacity publication-title: Stem Cells doi: 10.1002/stem.1821 – volume: 66 start-page: 2234 year: 2014 ident: R53 article-title: A CD8 T Cell/Indoleamine 2,3‐dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus publication-title: Arthritis Rheumatol doi: 10.1002/art.38674 – volume: 29 start-page: 29 year: 2016 ident: R9 article-title: Novel stem cell therapies for applications to wound healing and tissue repair publication-title: Surg Technol Int – volume: 2019 start-page: 1 year: 2019 ident: R43 article-title: Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells publication-title: Stem Cells Int doi: 10.1155/2019/7061408 – volume: 15 start-page: 2 year: 2013 ident: R44 article-title: The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? publication-title: Cytotherapy doi: 10.1016/j.jcyt.2012.10.002 – volume: 69 start-page: 1423 year: 2010 ident: R16 article-title: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.123463 – volume: 27 start-page: 2161 year: 2018 ident: R40 article-title: Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis publication-title: Lupus doi: 10.1177/0961203318804922 – volume: 56 start-page: 1175 year: 2007 ident: R17 article-title: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis publication-title: Arthritis Rheum doi: 10.1002/art.22511 – volume: 57 start-page: 1759 year: 2008 ident: R27 article-title: Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes publication-title: Diabetes doi: 10.2337/db08-0180 – volume: 106 start-page: 13445 year: 2009 ident: R37 article-title: GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3 + regulatory T cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0901944106 – volume: 135 start-page: 10 year: 2011 ident: R58 article-title: Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation publication-title: Immunol Lett doi: 10.1016/j.imlet.2010.09.006 – volume: 27 start-page: 1421 year: 2009 ident: R22 article-title: Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans publication-title: Stem Cells doi: 10.1002/stem.68 – volume: 3 year: 2018 ident: R39 article-title: B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex publication-title: JCI Insight doi: 10.1172/jci.insight.99863 – volume: 9 start-page: 149 year: 2018 ident: R47 article-title: Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus publication-title: Stem Cell Res Ther doi: 10.1186/s13287-018-0898-x – volume: 22 start-page: 2267 year: 2013 ident: R15 article-title: Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience publication-title: Cell Transplant doi: 10.3727/096368911X582769c – volume: 10 year: 2019 ident: R56 article-title: Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients publication-title: Nat Commun doi: 10.1038/s41467-019-10491-8 – volume: 36 start-page: 602 year: 2018 ident: R57 article-title: Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells publication-title: Stem Cells doi: 10.1002/stem.2779 – volume: 97 start-page: 13625 year: 2000 ident: R7 article-title: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.240309797 – volume: 8 start-page: 315 year: 2006 ident: R6 article-title: Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement publication-title: Cytotherapy doi: 10.1080/14653240600855905 – volume: 22 start-page: 3192 year: 2013 ident: R14 article-title: Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy publication-title: Stem Cells Dev doi: 10.1089/scd.2013.0023 – volume: 2014 start-page: 1 year: 2014 ident: R46 article-title: Association of TNF- α with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus publication-title: J Immunol Res doi: 10.1155/2014/169082 – volume: 37 start-page: 240 year: 2012 ident: R4 article-title: Lupus: an overview of the disease and management options publication-title: P T – volume: 75 start-page: 389 year: 2003 ident: R10 article-title: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation publication-title: Transplantation doi: 10.1097/01.TP.0000045055.63901.A9 – volume: 62 start-page: 2467 year: 2010 ident: R21 article-title: Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus publication-title: Arthritis & Rheumatism doi: 10.1002/art.27548 – volume: 193 start-page: 4381 year: 2014 ident: R29 article-title: Differential efficacy of human mesenchymal stem cells based on source of origin publication-title: J Immunol doi: 10.4049/jimmunol.1401636 – volume: 33 start-page: 1611 year: 2014 ident: R23 article-title: Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy publication-title: Clin Rheumatol doi: 10.1007/s10067-014-2754-4 – volume: 101 start-page: 2999 year: 2003 ident: R50 article-title: Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates publication-title: Blood doi: 10.1182/blood-2002-06-1830 – volume: 19 year: 2018 ident: R3 article-title: Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in nepalese population: a randomized control trial publication-title: BMC Nephrol doi: 10.1186/s12882-018-0973-7 – volume: 4 start-page: 206 year: 2009 ident: R49 article-title: Mesenchymal stem cell homing: the devil is in the details publication-title: Cell Stem Cell doi: 10.1016/j.stem.2009.02.001 – volume: 7 start-page: 37 year: 2016 ident: R8 article-title: Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy publication-title: Stem Cell Res Ther doi: 10.1186/s13287-016-0303-6 – volume: 169 start-page: 12 year: 2001 ident: R48 article-title: The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion publication-title: Cells Tissues Organs doi: 10.1159/000047856 – volume: 149 start-page: 918 year: 2015 ident: R19 article-title: Allogeneic bone marrow–derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with crohn’s disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.06.014 – volume: 99 start-page: 3838 year: 2002 ident: R11 article-title: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli publication-title: Blood doi: 10.1182/blood.V99.10.3838 – volume: 32 start-page: 252 year: 2014 ident: R26 article-title: Mesenchymal stem cells: immune evasive, not immune privileged publication-title: Nat Biotechnol doi: 10.1038/nbt.2816 – volume: 68 start-page: 1422 year: 2016 ident: R33 article-title: Prospective validation of the lupus impact Tracker: a patient-completed tool for clinical practice to evaluate the impact of systemic lupus erythematosus publication-title: Arthritis & Rheumatology doi: 10.1002/art.39601 – volume: 52 year: 2020 ident: R35 article-title: Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus publication-title: Immunity doi: 10.1016/j.immuni.2019.12.005 – volume: 22 start-page: 1062 year: 2008 ident: R13 article-title: Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L publication-title: Leukemia doi: 10.1038/sj.leu.2404996 – volume: 353 start-page: 2219 year: 2005 ident: R2 article-title: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis publication-title: N Engl J Med doi: 10.1056/NEJMoa043731 – volume: 371 start-page: 1579 year: 2008 ident: R51 article-title: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study publication-title: The Lancet doi: 10.1016/S0140-6736(08)60690-X – volume: 2020 start-page: 1 year: 2020 ident: R42 article-title: Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus publication-title: Stem Cells Int doi: 10.1155/2020/6518508 – volume: 9 start-page: 149 year: 2018 ident: 2024052110142839000_9.1.e000704.47 article-title: Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus publication-title: Stem Cell Res Ther doi: 10.1186/s13287-018-0898-x – ident: 2024052110142839000_9.1.e000704.50 doi: 10.1182/blood-2002-06-1830 – volume: 10 start-page: 933 year: 2018 ident: 2024052110142839000_9.1.e000704.20 article-title: A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus publication-title: Stem Cell Reports doi: 10.1016/j.stemcr.2018.01.029 – ident: 2024052110142839000_9.1.e000704.39 doi: 10.1172/jci.insight.99863 – ident: 2024052110142839000_9.1.e000704.6 doi: 10.1080/14653240600855905 – volume: 22 start-page: 2267 year: 2013 ident: 2024052110142839000_9.1.e000704.15 article-title: Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience publication-title: Cell Transplant doi: 10.3727/096368911X582769c – volume: 2014 start-page: 1 year: 2014 ident: 2024052110142839000_9.1.e000704.46 article-title: Association of TNF- α with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus publication-title: J Immunol Res doi: 10.1155/2014/169082 – volume: 69 start-page: 1623 year: 2017 ident: 2024052110142839000_9.1.e000704.30 article-title: Bone marrow-derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein-Interferon-β feedback loop publication-title: Arthritis & Rheumatology doi: 10.1002/art.40142 – ident: 2024052110142839000_9.1.e000704.59 doi: 10.1016/S0923-2508(01)01253-0 – ident: 2024052110142839000_9.1.e000704.10 doi: 10.1097/01.TP.0000045055.63901.A9 – ident: 2024052110142839000_9.1.e000704.16 doi: 10.1136/ard.2009.123463 – ident: 2024052110142839000_9.1.e000704.31 doi: 10.1177/0961203309348983 – volume: 2013 start-page: 1 year: 2013 ident: 2024052110142839000_9.1.e000704.52 article-title: Mscs: delivery routes and engraftment, cell-targeting strategies, and immune modulation publication-title: Stem Cells Int doi: 10.1155/2013/732742 – ident: 2024052110142839000_9.1.e000704.58 doi: 10.1016/j.imlet.2010.09.006 – ident: 2024052110142839000_9.1.e000704.29 doi: 10.4049/jimmunol.1401636 – ident: 2024052110142839000_9.1.e000704.25 doi: 10.1177/0963689719837897 – ident: 2024052110142839000_9.1.e000704.13 doi: 10.1038/sj.leu.2404996 – volume: 33 start-page: 1611 year: 2014 ident: 2024052110142839000_9.1.e000704.23 article-title: Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy publication-title: Clin Rheumatol doi: 10.1007/s10067-014-2754-4 – ident: 2024052110142839000_9.1.e000704.5 doi: 10.1073/pnas.0937635100 – ident: 2024052110142839000_9.1.e000704.17 doi: 10.1002/art.22511 – volume: 19 year: 2018 ident: 2024052110142839000_9.1.e000704.3 article-title: Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in nepalese population: a randomized control trial publication-title: BMC Nephrol doi: 10.1186/s12882-018-0973-7 – ident: 2024052110142839000_9.1.e000704.43 doi: 10.1155/2019/9757201 – volume: 36 start-page: 602 year: 2018 ident: 2024052110142839000_9.1.e000704.57 article-title: Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells publication-title: Stem Cells doi: 10.1002/stem.2779 – volume: 8 start-page: 1577 year: 2019 ident: 2024052110142839000_9.1.e000704.18 article-title: Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”—outcome report of 92 patients publication-title: Cells doi: 10.3390/cells8121577 – ident: 2024052110142839000_9.1.e000704.37 doi: 10.1073/pnas.0901944106 – volume: 7 start-page: 37 year: 2016 ident: 2024052110142839000_9.1.e000704.8 article-title: Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy publication-title: Stem Cell Res Ther doi: 10.1186/s13287-016-0303-6 – ident: 2024052110142839000_9.1.e000704.27 doi: 10.2337/db08-0180 – ident: 2024052110142839000_9.1.e000704.34 – ident: 2024052110142839000_9.1.e000704.42 doi: 10.1155/2020/4327965 – ident: 2024052110142839000_9.1.e000704.7 doi: 10.1073/pnas.240309797 – ident: 2024052110142839000_9.1.e000704.55 doi: 10.1146/annurev-pathol-011110-130230 – ident: 2024052110142839000_9.1.e000704.45 doi: 10.1177/0961203310361482 – volume: 16 start-page: 113 year: 2014 ident: 2024052110142839000_9.1.e000704.41 article-title: Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy publication-title: Arthritis Res Ther doi: 10.1186/ar4677 – ident: 2024052110142839000_9.1.e000704.49 doi: 10.1016/j.stem.2009.02.001 – volume: 40 year: 1997 ident: 2024052110142839000_9.1.e000704.32 article-title: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis & Rheumatism doi: 10.1002/art.1780400928 – ident: 2024052110142839000_9.1.e000704.21 doi: 10.1002/art.27548 – ident: 2024052110142839000_9.1.e000704.11 doi: 10.1182/blood.V99.10.3838 – volume: 29 start-page: 29 year: 2016 ident: 2024052110142839000_9.1.e000704.9 article-title: Novel stem cell therapies for applications to wound healing and tissue repair publication-title: Surg Technol Int – ident: 2024052110142839000_9.1.e000704.38 doi: 10.1002/stem.1821 – ident: 2024052110142839000_9.1.e000704.19 doi: 10.1053/j.gastro.2015.06.014 – ident: 2024052110142839000_9.1.e000704.54 doi: 10.1182/blood-2003-11-3909 – ident: 2024052110142839000_9.1.e000704.22 doi: 10.1002/stem.68 – volume: 27 start-page: 2161 year: 2018 ident: 2024052110142839000_9.1.e000704.40 article-title: Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis publication-title: Lupus doi: 10.1177/0961203318804922 – ident: 2024052110142839000_9.1.e000704.26 doi: 10.1038/nbt.2816 – volume: 371 start-page: 1579 year: 2008 ident: 2024052110142839000_9.1.e000704.51 article-title: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study publication-title: The Lancet doi: 10.1016/S0140-6736(08)60690-X – ident: 2024052110142839000_9.1.e000704.28 doi: 10.1155/2018/6241681 – ident: 2024052110142839000_9.1.e000704.14 doi: 10.1089/scd.2013.0023 – volume: 52 year: 2020 ident: 2024052110142839000_9.1.e000704.35 article-title: Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus publication-title: Immunity doi: 10.1016/j.immuni.2019.12.005 – volume: 68 start-page: 1422 year: 2016 ident: 2024052110142839000_9.1.e000704.33 article-title: Prospective validation of the lupus impact Tracker: a patient-completed tool for clinical practice to evaluate the impact of systemic lupus erythematosus publication-title: Arthritis & Rheumatology doi: 10.1002/art.39601 – volume: 10 year: 2019 ident: 2024052110142839000_9.1.e000704.56 article-title: Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients publication-title: Nat Commun doi: 10.1038/s41467-019-10491-8 – ident: 2024052110142839000_9.1.e000704.2 doi: 10.1056/NEJMoa043731 – volume: 66 start-page: 2234 year: 2014 ident: 2024052110142839000_9.1.e000704.53 article-title: A CD8 T Cell/Indoleamine 2,3‐dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus publication-title: Arthritis Rheumatol doi: 10.1002/art.38674 – volume: 12 start-page: 64 year: 2014 ident: 2024052110142839000_9.1.e000704.12 article-title: A Phase 2 study of allogeneic mesenchymal stromal cells for Luminal crohn’s disease refractory to biologic therapy publication-title: Clinical Gastroenterology and Hepatology doi: 10.1016/j.cgh.2013.06.021 – volume: 14 start-page: 423-431 year: 2017 ident: 2024052110142839000_9.1.e000704.36 article-title: The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus publication-title: Cell Mol Immunol doi: 10.1038/cmi.2015.89 – ident: 2024052110142839000_9.1.e000704.1 doi: 10.1038/nrdp.2016.39 – ident: 2024052110142839000_9.1.e000704.24 doi: 10.1136/annrheumdis-2017-211073 – ident: 2024052110142839000_9.1.e000704.48 doi: 10.1159/000047856 – volume: 37 start-page: 240 year: 2012 ident: 2024052110142839000_9.1.e000704.4 article-title: Lupus: an overview of the disease and management options publication-title: P T – ident: 2024052110142839000_9.1.e000704.44 doi: 10.1016/j.jcyt.2012.10.002 |
| SSID | ssj0001213780 |
| Score | 2.3965466 |
| Snippet | BackgroundReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to... Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform... Background Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e000704 |
| SubjectTerms | Autoimmunity B-Lymphocytes Bone marrow Clinical Trials and Drug Discovery Disease Female Humans Immune system Immunology Lupus Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic - drug therapy Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cells Patients Response rates Transforming Growth Factor beta Umbilical Cord |
| SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3LbtQw0IIiVb0g3gQKMhLigEg3jhPHPgJqVRBwaSuVU-RndxGbrDbZw_4LH4vHTkIXoYpTJD_ix8x4Zux5IPTaMymjs0qnjsIzI89EygviUsKkELLUlJsQ7fMbO70oPl-Wl4OiGFN9rTbdkVr-iP4MEKGp6WdiRmYW2FlWHMG19G10BxKTABaL7-fX7lQIrfj4eEkoi7_zmOA1rtj9AO2Db6hnrOCQ4sfZ4UchbP-_ZM2_TSav8aCTe-juIDzi9xHa99Et2zxA-1-H5_GH6NeZdLbfvsML8PoYjzU82Gxg2Rg8ekLidTSOtXjRYIlXc8_N8Cccknjg1uHNEqxmoSGop3gJTkp6vl36gq5ft_CFO_8Oug-xWTsMl7p4Ml33Q7h1SOezxWdfjh-hi5Pj84-n6ZB-IVWeMPuUKm6lUppSKp0kyhpFitI454VIQyomS2UUd85URWaM0tKr2sppVjBiMu3Prcdor2kb-xRhQ5S2UigligoyA3MhZZlbznhhmJYyQW88KOqBfLo6aCaU1QF8NYCvjuBLUDZCq9ZDEHPIpfHzpi5vpy6rGMHjpsYfAAWmhhB8OxS066t6oOVaG0kLlZXGemmykkY5mSvGreZKcSp5gg5HBPqzpJxxWK7flgS9mqo9LQOwZGPbTWgjIMVilSfoScS3aSYj1iao2sHEnanu1jSLeYgXLnIv42f5s__d5OfoIFIMGCUfor1-vbEvvOjVq5eB3n4DaEcumA priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0IIeEBfEm9CCjIQ4IKImceI4R0CtCgIupVJvkccP7Vbd7GqzOey_9GOZcR7sIlQunCI548T2zHhm7Hkw9haFlDVJaWIv6JpRJVWs8tTHqdRVpQsjlA3ZPn_Is4v862VxuVPqi3zC-vTA_cIdG6tFDklhHYruUlvwOgOpnFEASugQ5osyb8eY6k9XUlGq8RozFfL4ult1LdIE2l4kF6kw211YXO2Jo5C1_2-q5p8ekzsi6PQhezDojvxjP-ZH7I5rHrN734fb8Sfs5lx7t9l-4HMK-hh3NT64bHDdWD4GQvJ17xvr-Lzhmq9mKMz4Fx5qePCl592CnGYJkKxTvqAYJTPbLrCh3ayX9KQj_5a6D6lZW05nunzyXMdf-HWo5rPl599OnrKL05Ofn8_iofpCDMiXm1iAchrACCG01yk4C2leWO9Rh7RpKXUBFpT3tswTa8FotLTBG5nL1CYGt61n7KBZNu4F4zYF43QFUOUlFQZWldZF5pRUuZVG64i9Q1TUA_e0dTBMhKwDzmrCWd3jLGLJiK3aDDnMqZTG9W1d3k9dVn0Cj9uAPxEJTICUezs0IEXWA0XW_6LIiB2NBPR7SplUNF1cloi9mV4jKxOydOOWXYCpqMJimUXseU9v00gooBm1Qfx4uUeJe0Pdf9PMZyFdeJWhip9kL__H3A7Z_Z6FyF_5iB1s1p17hVrZBl4HBvwFEQw7Xg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokRAXxJtAQUZCHBBRkzixnRMC1Kog4FIq7S3ys7uomyx5HPa_8GPxOE7aRWhPkRI7cfTNeMbj8XwIvXFGSquEqdgS2GbkSRnzPLVxSkVZikIRrn21zx_07CL_uigWIeDWhbTKaU70E7VuFMTIjzPKOXVTKSUfNr9jYI2C3dVAoXGAbkPpMpBqtmA3YiwpYXzazEwJPb4aNkPnJMOtwMA6Aj3bgVz_2jFKvnb__xzOf_Mmbxii0_voXvAg8ccR8gfolqkfojvfwx75I_TnXFjTb9_jFRz9mOY2HBI3sKg1no5D4nbMkDV4VWOBN0tn0vAX7Jk8cGPxsIbUWWgIa1S8hpNKarlduxtd3zZwhcB_B91DgdYOQ2QXz_nr7hO29Zw-W3z-7eQxujg9-fn5LA4cDLF02tnHRHIjpFSEEGFFKo2WaV5oa50nqVNGRSG15NZqlidaSyXceltaRXOa6kQ5tJ6gw7qpzTOEdSqVEaWUZc6AHpiXQhSZAVQ1VUJE6K2Dogo61FV-eUJo5TGrALNqxCxCyYRWpUIlcyDUuNrX5d3cZTOW8djX-BOIwNwQKnD7G017WQWFrpQWJJdJoY1zKZnQ0opMUm4Ul5ITwSN0NAnQ9S9dC3GEXs-PnUIDWKI2zeDblMCzyLIIPR3lbR4JHGt2PqF7OduRxJ2h7j6pV0tfNLzMnKOfZM_3D-sFujsqB-QjH6HDvh3MS-d19fKVV62_tg0xGg priority: 102 providerName: ProQuest |
| Title | Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE |
| URI | https://lupus.bmj.com/content/9/1/e000704.full https://www.ncbi.nlm.nih.gov/pubmed/35820718 https://www.proquest.com/docview/2688684763 https://www.proquest.com/docview/2689059372 https://pubmed.ncbi.nlm.nih.gov/PMC9277402 https://doaj.org/article/cda34b05de2647adbfa2b68ec8bb83a8 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfGJiFeEN8rjMpIiAdEIN92HhDapk4D0QmxFZWnyJ-0qE1L0kj0f-GP5c5JCkXVJF5iKbGT2Hfnu7PP9yPkOSgprXymPBvhNiP3M4_HgfWCVGSZSFTEtcv2eZGej-IP42S8Rzp4q3YAq52uHeJJjcrZ658_1u9A4N-2iCRvZvWyroDc4FahysPsoAegmBgCGgxba79Zcgki5rDUQmA9mAeybp9z51tA28j59y195dL677JF_w2p_EtHnd0ht1vjkh433HCX7JniHrk5bLfP75Nfl8Ka1foVneKpkG7ao21MBxWFpt1JSVo2wbOGTgsq6HIC2o6-pw7kgy4srecYVYsV0X2lczzEpCbrOdyoVuUCS9wTqLB5m7u1orjoSzeh7fAJWzq4nzW9_Dh4QEZng6vTc6-FZ_AkCO7KiyQ3QkoVRZGwIpBGyyBOtLVgZOqApSKRWnJrNYt9raUS4IpLq9I4DbSvYF57SPaLRWEOCdWBVEZkUmYxQ-RgngmRhIanPNapEqJHXgAp8o47cue5RGnuaJYjzfKGZj3id9TKVZvkHLE2Ztc1eblpsmwyfFxX-QRZYFMRk3O7G4vyW97Keq60iGLpJ9qAtcmEllaEMuVGcSl5JHiPHHUM9KdLYcqxuzAsPfJs8xhkHYklCrOoXZ0MIRhZ2COPGn7b_AmeeAZzEV7Otjhx61e3nxTTicsnnoXgA_jh4_8ZiCfkViMqGLh8RPZXZW2egnm2kn1yg40ZXLOvV31ycHw6HH6B8mRw8elz3y159J1Y_gYIGkEa |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB61RQIuiJ1AgUECDgirtscejw8IsbRKaNpLWyk3d1YS1NghjoXyX_gN_Ebe85I2COXWkyV7xh7rvXnLvOUj5DUoKaP9RHuOYZhR-KknosB5AZdpKmPNhKm7fR7z_ln0bRSPtsifrhYG0yo7mVgLalNoPCPfC7kQHEQpZx9nPz1EjcLoageh0bDFoV3-Apet_DD4CvR9E4YH-6df-l6LKuAp4LeFx5SwUinNGJNOBsoaFUSxcQ5sIxMkXMbKKOGcSSLfGKUleJDKaR7xwPgavg_v3SY3QPH66Owlo-TKmU7AEtEFTwPG9y6qWVUCJ4LHh9oY4eC21fTHmhKssQL-Z-D-m6d5RfEd3CV3WouVfmpY7B7Zsvl9cvOojck_IL9PpLOL5Xs6wVKTTpbSNlGEytzQrvySzpuMXEsnOZV0NgYVSge0Rg6hhaPVFFN1cSD6xHSKlVF6vJzCjXIxL_CKgYYSp7cNYUuKJ8l0lS8Pn3DzGkNoSU-G-w_J2bVQ5xHZyYvcPiHUBEpbmSqVRgnCEYtUyji0yEWGayl75C2QImv3bJnV7hDjWU2zDGmWNTTrEb-jVqbbzukI4HGxacq71ZRZ0zZk0-DPyAKrgdjxu75RzL9nrQDJtJEsUn5sLJiwiTTKyVBxYbVQSjApemS3Y6DLX7rcND3yavUYBAgSS-a2qOoxKeI6JmGPPG74bbUSLKMGGxRenqxx4tpS15_kk3HdpDwNwbHww6ebl_WS3OqfHg2z4eD48Bm53WwUzIXeJTuLeWWfg8W3UC_qbUbJ-XXv67_Pm3Ex |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB61qVRxQewECgwScEBYsT32eHxAiNJEDS1RRanUmzsrCWrskEUo_4Vfwq_jPS9pg1BuPVmyZ-yx3jZv3vIR8gqMlNF-oj3HMMwo_NQTUeC8gMs0lbFmwpTdPgf88Cz6fB6fb5E_TS0MplU2OrFU1KbQeEbeCbkQHFQpZx1Xp0WcHPQ-TH56iCCFkdYGTqNikSO7_AXu2-x9_wBo_ToMe91vnw69GmHAU8B7c48pYaVSmjEmnQyUNSqIYuMc7JNMkHAZK6OEcyaJfGOUluBNKqd5xAPja1gLvHeb7CToFbXIzn53cPL12glPwBLRhFIDxjuXi8liBnwJ_h_aZgSH21bjH2smsUQO-N9299-szWtmsHeH3K73r_RjxXB3yZbN75HdL3WE_j75fSqdnS_f0REWnjSaldZpI1TmhjbFmHRa5edaOsqppJMhGFTapyWOCC0cXYwxcRcHoodMx1gnpYfLMdyYzacFXjHsMMPpdXvYGcVzZbrKnodPuGmJKLSkp8fdB-TsRujzkLTyIrePCTWB0lamSqVRguDEIpUyDi3ylOFayjZ5A6TIagmeZaVzxHhW0ixDmmUVzdrEb6iV6bqPOsJ5XG6a8nY1ZVI1Edk0eB9ZYDUQ-3-XN4rp96xWJ5k2kkXKj42FDW0ijXIyVFxYLZQSTIo22WsY6OqXrkSoTV6uHoM6QWLJ3BaLckyKKI9J2CaPKn5brQSLqoHR4eXJGieuLXX9ST4ali3L0xDcDD98snlZL8guyHR23B8cPSW3KjnBxOg90ppPF_YZbP_m6nktZ5Rc3LRo_wXPT3bM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+immunological+effects+and+clinical+response+in+a+phase+I+trial+of+umbilical+cord+mesenchymal+stromal+cells+in+patients+with+treatment+refractory+SLE&rft.jtitle=Lupus+science+%26+medicine&rft.au=Kamen%2C+Diane+L&rft.au=Wallace%2C+Caroline&rft.au=Li%2C+Zihai&rft.au=Wyatt%2C+Megan&rft.date=2022-07-01&rft.issn=2053-8790&rft.eissn=2053-8790&rft.volume=9&rft.issue=1&rft.spage=e000704&rft_id=info:doi/10.1136%2Flupus-2022-000704&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_lupus_2022_000704 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2053-8790&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2053-8790&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2053-8790&client=summon |